SCM
TVTX icon

Scopia Capital Management’s Travere Therapeutics TVTX Stock Holding History

Scopia Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-741,214
Closed -$20.2M – 20
2020
Q4 		$20.2M Sell
741,214
-590,936
-44% -$13.8M 2.56% 11
2020
Q3 		$24.6M Sell
1,332,150
-453,759
-25% -$8.82M 2.91% 11
2020
Q2 		$36.5M Buy
1,785,909
+48,475
+3% +$772K 4.01% 9
2020
Q1 		$25.3M Sell
1,737,434
-274,263
-14% -$4.13M 2.32% 13
2019
Q4 		$28.6M Sell
2,011,697
-1,208,201
-38% -$15.4M 2.21% 16
2019
Q3 		$37.3M Sell
3,219,898
-664,793
-17% -$11M 2.18% 14
2019
Q2 		$78M Sell
3,884,691
-330,281
-8% -$6.52M 3.47% 14
2019
Q1 		$95.4M Sell
4,214,972
-1,695,881
-29% -$37.5M 3.52% 12
2018
Q4 		$134M Sell
5,910,853
-608,572
-9% -$15.1M 4.54% 8
2018
Q3 		$187M Hold
6,519,425
– – 3.6% 11
2018
Q2 		$178M Sell
6,519,425
-139,741
-2% -$3.72M 3.11% 14
2018
Q1 		$149M Hold
6,659,166
– – 2.98% 18
2017
Q4 		$140M Hold
6,659,166
– – 2.52% 16
2017
Q3 		$166M Buy
6,659,166
+686,055
+11% +$15.1M 2.62% 13
2017
Q2 		$116M Buy
5,973,111
+89,455
+2% +$1.62M 2.39% 17
2017
Q1 		$109M Buy
5,883,656
+794,022
+16% +$15.5M 2.01% 20
2016
Q4 		$96.3M Buy
5,089,634
+836,746
+20% +$17.1M 1.83% 20
2016
Q3 		$95.2M Buy
4,252,888
+441,067
+12% +$8.4M 1.68% 20
2016
Q2 		$67.9M Buy
3,811,821
+213,599
+6% +$3.46M 1.4% 23
2016
Q1 		$49.2M Buy
3,598,222
+3,229,087
+875% +$49M 0.92% 25
2015
Q4 		$7.12M Buy
+369,135
New +$7.37M 0.14% 31

Other funds holding TVTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Scopia Capital Management's TVTX Position: Q1 2021 in Review

Scopia Capital Management sold out of Travere Therapeutics (TVTX) in Q1 2021, closing a stake of 741,214 shares — an estimated $20.2M sold.

Scopia Capital Management first reported a position in TVTX in Q4 2015 and held it in 21 quarters. The position peaked at $187M in Q3 2018. 150 funds tracked by Wall St. Rank hold TVTX as of Q1 2021.

  • Scopia Capital Management reported no remaining Travere Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Scopia Capital Management sold 741,214 Travere Therapeutics shares in Q1 2021, an estimated $20.2M.
  • Scopia Capital Management first reported a position in Travere Therapeutics in Q4 2015 and held it in 21 quarters.
  • Scopia Capital Management's Travere Therapeutics position peaked at $187M in Q3 2018.
  • 150 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2021.

Based on Scopia Capital Management's 13F filing for Q1 2021, filed 17 May 2021.